294 related articles for article (PubMed ID: 10492184)
1. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status.
Jacobsen SJ; Jacobson DJ; Girman CJ; Roberts RO; Rhodes T; Guess HA; Lieber MM
J Urol; 1999 Oct; 162(4):1301-6. PubMed ID: 10492184
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota.
Burke JP; Jacobson DJ; McGree ME; Roberts RO; Girman CJ; Lieber MM; Jacobsen SJ
Urology; 2006 Jan; 67(1):22-5. PubMed ID: 16413325
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal changes in peak urinary flow rates in a community based cohort.
Roberts RO; Jacobsen SJ; Jacobson DJ; Rhodes T; Girman CJ; Lieber MM
J Urol; 2000 Jan; 163(1):107-13. PubMed ID: 10604326
[TBL] [Abstract][Full Text] [Related]
4. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
[TBL] [Abstract][Full Text] [Related]
5. Incidence rates and risk factors for acute urinary retention: the health professionals followup study.
Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
J Urol; 1999 Aug; 162(2):376-82. PubMed ID: 10411042
[TBL] [Abstract][Full Text] [Related]
6. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
8. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia.
St Sauver JL; Jacobson DJ; McGree ME; Lieber MM; Jacobsen SJ
Am J Epidemiol; 2006 Oct; 164(8):760-8. PubMed ID: 16905643
[TBL] [Abstract][Full Text] [Related]
9. Natural history of prostatism: risk factors for acute urinary retention.
Jacobsen SJ; Jacobson DJ; Girman CJ; Roberts RO; Rhodes T; Guess HA; Lieber MM
J Urol; 1997 Aug; 158(2):481-7. PubMed ID: 9224329
[TBL] [Abstract][Full Text] [Related]
10. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
11. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
[TBL] [Abstract][Full Text] [Related]
13. The natural history of benign prostatic hyperplasia.
Fitzpatrick JM
BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.
Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; Hebbring SJ; Cunningham JM; Thibodeau SN; Lieber MM; Jacobsen SJ
Prostate; 2006 Mar; 66(4):392-404. PubMed ID: 16302261
[TBL] [Abstract][Full Text] [Related]
15. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
Kaplan SA; Olsson CA; Te AE
J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
[TBL] [Abstract][Full Text] [Related]
16. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia.
Burke JP; Rhodes T; Jacobson DJ; McGree ME; Roberts RO; Girman CJ; Lieber MM; Jacobsen SJ
Am J Epidemiol; 2006 Jul; 164(1):41-6. PubMed ID: 16611664
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
Lukacs B; Leplège A; Thibault P; Jardin A
Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
[TBL] [Abstract][Full Text] [Related]
18. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
19. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.
St Sauver JL; Jacobson DJ; Girman CJ; Lieber MM; McGree ME; Jacobsen SJ
J Urol; 2006 Mar; 175(3 Pt 1):1018-22; discussion 1022. PubMed ID: 16469608
[TBL] [Abstract][Full Text] [Related]
20. Management of lower urinary tract symptoms secondary to benign prostatic hyperplasia with open prostatectomy: results of a contemporary series.
Helfand B; Mouli S; Dedhia R; McVary KT
J Urol; 2006 Dec; 176(6 Pt 1):2557-61; discussion 2561. PubMed ID: 17085158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
